JP2016522177A - ジヒドロピラジノ−ピラジンによる癌治療 - Google Patents

ジヒドロピラジノ−ピラジンによる癌治療 Download PDF

Info

Publication number
JP2016522177A
JP2016522177A JP2016509050A JP2016509050A JP2016522177A JP 2016522177 A JP2016522177 A JP 2016522177A JP 2016509050 A JP2016509050 A JP 2016509050A JP 2016509050 A JP2016509050 A JP 2016509050A JP 2016522177 A JP2016522177 A JP 2016522177A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
dihydropyrazino
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016509050A
Other languages
English (en)
Japanese (ja)
Inventor
ライモン ヘザー
ライモン ヘザー
ク シュイチャン
ク シュイチャン
ツジ トシヤ
ツジ トシヤ
マエ ヘゲ クリステン
マエ ヘゲ クリステン
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2016522177A publication Critical patent/JP2016522177A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016509050A 2013-04-17 2014-04-16 ジヒドロピラジノ−ピラジンによる癌治療 Pending JP2016522177A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813026P 2013-04-17 2013-04-17
US61/813,026 2013-04-17
PCT/US2014/034303 WO2014172424A1 (fr) 2013-04-17 2014-04-16 Traitement du cancer par des dihydropyrazino-pyrazines

Publications (1)

Publication Number Publication Date
JP2016522177A true JP2016522177A (ja) 2016-07-28

Family

ID=50732330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509050A Pending JP2016522177A (ja) 2013-04-17 2014-04-16 ジヒドロピラジノ−ピラジンによる癌治療

Country Status (5)

Country Link
US (1) US20140314673A1 (fr)
EP (1) EP2986297A1 (fr)
JP (1) JP2016522177A (fr)
TW (1) TW201526894A (fr)
WO (1) WO2014172424A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7498795B2 (ja) 2020-04-17 2024-06-12 チェンドゥ バイユー ファーマシューティカル カンパニー リミテッド イミダゾリジノン誘導体及びその医薬における応用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218763A1 (fr) 2013-04-17 2023-08-02 Signal Pharmaceuticals, LLC 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one pour le traitement du glioblastome multiforme
CA2908957C (fr) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Polytherapie comportant un compose dihydropyrazino-pyrazine et un antagoniste d'un recepteur des androgenes pour le traitement du cancer de la prostate
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
WO2014172426A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
WO2014172423A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Formulations pharmaceutiques, procédés, formes solides et méthodes d'utilisation associés à la 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) * 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131551A4 (fr) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
CN108342355B (zh) * 2018-01-10 2021-06-18 南京艾维艾康生物技术有限公司 原始卵泡激活剂及其在人卵巢皮质培养液中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631003T3 (es) * 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
EP2320894B1 (fr) * 2008-08-20 2016-12-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Chimioprévention de carcinome à cellules squameuses de la tête et du cou
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2493472B1 (fr) * 2009-10-26 2016-12-07 Signal Pharmaceuticals, LLC Procédés de synthèse et de purification de composés hétéroaryles
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7498795B2 (ja) 2020-04-17 2024-06-12 チェンドゥ バイユー ファーマシューティカル カンパニー リミテッド イミダゾリジノン誘導体及びその医薬における応用

Also Published As

Publication number Publication date
TW201526894A (zh) 2015-07-16
EP2986297A1 (fr) 2016-02-24
WO2014172424A1 (fr) 2014-10-23
US20140314673A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
JP6382945B2 (ja) ジヒドロピラジノ−ピラジンによる癌治療
US10391092B2 (en) Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
JP2021102637A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016522177A (ja) ジヒドロピラジノ−ピラジンによる癌治療
JP6382946B2 (ja) ジヒドロピラジノ−ピラジンによる癌治療
TWI635862B (zh) 使用ｔｏｒ激酶抑制劑之癌症治療
JP2017514806A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
JP2017514805A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法